REGENXBIO Inc. (RGNX) company profile
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
About Regenxbio
Biological Products, (No Diagnostic Substances), SIC 2836
REGENXBIO Inc. is a clinical-stage biotechnology company that focuses on the development and commercialization of gene therapies. The company utilizes its proprietary NAV Technology Platform to deliver genetic medicines for severe conditions. Its pipeline includes surabgene lomparvovec, RGX-121, and RGX-111, which are evaluated across clinical studies such as AAVIATE, ALTITUDE, and ATMOSPHERE. REGENXBIO provides development services, licensing rights, and technology access to partners. Its customers and collaborators primarily consist of global pharmaceutical and biotechnology companies, such as AbbVie and Nippon Shinyaku, as well as research institutions.
The company operates within the United States and maintains business relationships across international regions, including Ireland, Japan, Germany, and the United Arab Emirates. Its facilities include sites along Medical Center Drive in Maryland and leased space in New York. REGENXBIO is headquartered in Rockville, Maryland.
Summary of the business section of Regenxbio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- REGENXBIO Inc.
- Headquarters
- Rockville, MD
- Address
- 9804 Medical Center Drive 20850
- Phone
- (240) 552-8181
- Website
- regenxbio.com
- Employees
- 371, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Washington, District of Columbia
Stock & identifiers
- Ticker
- RGNX
- Exchange
- Nasdaq
- IPO date
- Sep 17, 2015
- Shares outstanding
- 66M, Jul 31, 2026
- Public float
- $385.01M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1590877
- CUSIP
- 75901B107
- ISIN
- US75901B1070
- FIGI
- BBG007Z9V591
- Share class FIGI
- BBG007Z9V5C7
- LEI
- 549300EOES47LATSET33
- EIN
- 47-1851754
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Curran Simpson | Chief Executive Officer, Director | 338,053 |
| Craig Malzahn | Chief Technology Officer | 109,737 |
| Mitchell Chan | Chief Financial Officer | 147,120 |
| Patrick J. Christmas | Chief Strategy & Legal Officer | 240,690 |
| Steve Pakola | Chief Medical Officer | 240,263 |
| Olivier Danos | Chief Scientific Officer | 226,348 |
| Gregory Austin Ciongoli | Director | 118,035 |
| Daniel Tasse | Director | 28,861 |
| George V. Migausky | Director | 28,861 |
| Jean Bennett | Director | 28,861 |
| Jennifer Zachary | Director | 31,871 |
| Argeris N. Karabelas | Director | 28,861 |
| David C. Stump | Director | 28,861 |
| Kenneth T. Mills | Director | 495,925 |
| Allan M. Fox | Director | 2,911,327 |
| Alexandra Glucksmann | Director | 28,861 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.20M | $9.33M | $1.92M | $63 | – |
| FY2024 Curran Simpson | $4.78M | $1.87M | $2.76M | $34 | – |
| FY2024 Kenneth TMills | $5.51M | -$253.33K | $2.76M | $34 | – |
| FY2023 | $5.92M | $3.05M | $2.96M | $79 | – |
| FY2022 | $5.75M | $1.41M | $1.99M | $55 | $114 |
| FY2021 | $8.62M | $2.65M | $3.21M | $80 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Curran Simpson President and Chief Executive Officer | $665.51K | – | $777.45K | $2.35M | $387.33K | $20.13K | $4.20M | -12% |
| Stephen Pakola, M.D. EVP, Chief Medical Officer | $543.99K | – | $505.34K | $509.23K | $220.86K | $20.13K | $1.80M | -33% |
| Patrick J. Christmas EVP, Chief Strategy and Legal Officer | $520.90K | $200.00K | – | $1.10M | $203.67K | $20.13K | $2.04M | -25% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 17, 2015
- Offer price
- $22.00
- Securities offered
- 6,300,000
- Gross proceeds
- $138.60M
- Exchange
- Nasdaq
- First trading day
- Sep 17, 2015
- First-day close
- $30.45+38.4%
- Lock-up ends (est.)
- Mar 15, 2016
“The initial public offering price is $22.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 27, 2026, we employed 371 full-time employees, of which 296 were engaged in research and development activities, including preclinical, clinical and manufacturing related functions, and 75 were engaged in general administrative activities, including commercial, corporate development, finance, legal, human resources, information technology, fac”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 17, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 9, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 7, 2013 | Name change | Name changed from ReGenX Biosciences, LLC to REGENXBIO Inc. |
See a number that looks wrong?